Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

This study has been terminated.
(An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.)
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01646125
First received: June 26, 2012
Last updated: January 23, 2017
Last verified: January 2017

June 26, 2012
January 23, 2017
November 2012
November 2015   (Final data collection date for primary outcome measure)
Progression Free Survival (PFS) [ Time Frame: 16 months ]
Compared PFS between the treatment of AUY922 to comparators Pemetrexed or Docetaxel. Progression-free survival (PFS) based on local investigator assessment per RECIST 1.1 was the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient had not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Progression Free Survival (PFS) [ Time Frame: up to 12 months ]
To compare PFS between the treatment of AUY922 to comparators Pemetrexed or Docetaxel. PFS will be based on local investigator assessment per RECIST 1.1
Complete list of historical versions of study NCT01646125 on ClinicalTrials.gov Archive Site
  • Overall Response Rate (ORR) [ Time Frame: 16 months ]
    ORR was to be compared between treatment arms. The ORR was to be based on local investigator assessment per Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1). Per this criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.This outcome measure was originally planned to be analyzed up to 24 months. The DMC recommendation at the IA was to stop the study for futility. As a result, collection of all the efficacy assessments was stopped at that time.
  • Overall Survival (OS) [ Time Frame: from randomization until death up to death ]
    OS is defined as the time from the date of randomization to date of death due to any cause. If a death has not been observed by the date of analysis cutoff, then OS was to be censored at the last known date patient was alive.
  • Disease Control Rate (DCR) [ Time Frame: baseline, until disease progression up to 24 months ]
    Duration of DCR will be compared between treatment arms. The duration of DCR will be based on local investigator assessment per RECIST 1.1
  • Time to Response (TRR) [ Time Frame: baseline, until disease progression up to 24 months ]
    TTR was to compare between treatment arms. The TTR was to be based on local investigator assessment per RECIST 1.1
  • Duration of Response (DOR) [ Time Frame: baseline, until disease progression up to 24 months ]
    The DOR will be compared between treatment arms. The DOR will be based on local investigator assessment per RECIST 1.1
  • Rate of Adverse Events (AEs) [ Time Frame: baseline, until disease progression up to 24 months ]
    To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.
  • Change in Laboratory Paramenters [ Time Frame: baseline, until disease progression up to 24 months ]
    Changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), Dose interruptions, reductions and dose intensity.
  • Time to Progression (TTP) [ Time Frame: baseline, until disease progression up to 24 months ]
    TTP will be compared between treatment arms. The TTP will be based on local investigator assessment per RECIST 1.1
  • Overall Survival (OS) [ Time Frame: from randomization until death up to 24 months ]
    OS is defined as the time from the date of randomization to date of death due to any cause. If a death has not been observed by the date of analysis cutoff, then OS will be censored at the date of last contact.
  • Overall Response Rate (ORR) [ Time Frame: baseline, until disease progression up to 24 months ]
    ORR will be compared between treatment arms. The ORR will be based on local investigator assessment per RECIST 1.1
  • Disease Control Rate (DCR) [ Time Frame: baseline, until disease progression up to 24 months ]
    Duration of DCR will be compared between treatment arms. The duration of DCR will be based on local investigator assessment per RECIST 1.1
  • Time to Progression (TTP) [ Time Frame: baseline, until disease progression up to 24 months ]
    TTP will be compared between treatment arms. The TTP will be based on local investigator assessment per RECIST 1.1
  • Duration of Response (DOR) [ Time Frame: baseline, until disease progression up to 24 months ]
    The DOR will be compared between treatment arms. The DOR will be based on local investigator assessment per RECIST 1.1
  • Rate of Adverse Events (AEs) [ Time Frame: baseline, until disease progression up to 24 months ]
    To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.
  • Rate of serious Adverse events (SAEs) [ Time Frame: baseline, until disease progression up to 24 months ]
    To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.
  • Change in laboratory parameters [ Time Frame: baseline, until disease progression up to 24 months ]
    Changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), Dose interruptions, reductions and dose intensity.
Not Provided
Not Provided
 
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment

The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.

The primary purpose of this study was to compare the efficacy of AUY922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced NSCLC, whose tumors harbored EGFR activating mutations, and had developed resistance to EGFR TKI.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Advanced Non Small Cell Lung Cancer (NSCLC)
  • Drug: AUY922
    AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
  • Drug: Docetaxel
    Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
    Other Name: TAXOTERE
  • Drug: Pemetrexed
    Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
    Other Name: ALIMTA
  • Experimental: AUY922 arm

    Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.

    AUY922 was to be administered weekly.

    Intervention: Drug: AUY922
  • Active Comparator: chemotherapy arm

    Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.

    Pemetrexed or docetaxel was to be was to be given once every three weeks.

    Interventions:
    • Drug: Docetaxel
    • Drug: Pemetrexed
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
52
November 2015
November 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.
  2. Patients must have EGFR gene mutation in their tumors. This can be source - documented by one of the following:

    • Provide a pathology report that indicates the patient's tumor had EGFR activating mutation in the past.

    Or:

    • Perform testing (local or central) in an archival tumor or a fresh baseline biopsy tumor tissue to show the presence of EGFR activating mutation.

  3. Patients must have documented clinical benefit (CR, PR, or patients with SD for 6 months or greater) on prior EGFR TKI (e.g. erlotinib or gefitinib) followed by documented progression according to RECIST.
  4. Patients must have received prior platinum containing treatment.
  5. WHO performance status of 0-1

Exclusion Criteria:

  1. Patients who have received more than two prior lines of antineoplastic therapy for advanced disease. Chemotherapy administered as neoadjuvant or adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study.
  2. Evidence of spinal cord compression or current evidence of CNS metastases. Screening CT/MRI of the brain is mandatory. Note: Patients who have been treated for CNS metastases by radiation or gamma knife surgery, who been stable for at least 2 months and have discontinued high dose corticosteroids will be eligible for protocol participation
  3. Prior treatment with an HSP90 inhibitor
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   France,   Hong Kong,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Norway,   Poland,   Spain,   Taiwan,   United Kingdom
Australia
 
NCT01646125
CAUY922A2207
2012-001050-25 ( EudraCT Number )
Yes
Not Provided
Not Provided
Not Provided
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP